Alivus Life Sciences Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹689Cr
- +6% YoY
- +2.4% QoQ
- Net profit
- ₹163Cr
- +14.8% YoY
- +8.7% QoQ
- Margin
- 31%
- 0 pp YoY
- −3 pp QoQ
Guidance rank: #71 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins.
From Alivus Life Sciences Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business.
- Overall sales volume growth across segments is significant and expected to persist.
- New product launches contribute to growth, though not yet a major revenue driver.
- Capacity expansions (Solapur greenfield, brownfield expansions at Ankleshwar and Dahej) will enable volume and revenue growth post ramp-up.
- Solapur Phase 1 expected to start with 40-50% utilization, scaling to 60-70% gradually.
- New launches and pipeline buildup (especially complex molecules and high-potent APIs) underpin medium- to long-term growth.
- CDMO business ramping up with new projects commencing, supporting future revenue momentum.
2 more points from Alivus Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alivus Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments.
- Entire capex funded through internal accruals.
- Investments focus on building new capabilities at Solapur (greenfield project) and strengthening the R&D platform.
- Capacity expansion to increase from 1,198 KL in FY24 to a planned 2,690 KL by FY28.
- Solapur facility: Phase 1 includes 370 KL for BI block and 120 KL for API block, with 40-50% initial utilization.
- Brownfield expansions at Ankleshwar and Dahej, with rapid ramp-up expected within 2-3 quarters.
- Solapur has land bank for additional 700-800 KL capacity, offering runway for 3-4 years.
2 more points from Alivus Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alivus Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Alivus Life Sciences operates primarily on long-term contracts in its CDMO business.
- In the generic API segment, contracts are fewer and typically short-term, lasting about 1-2 years.
- The company prefers short to medium-term contracts to maintain flexibility due to a dynamic environment.
2 more points from Alivus Life Sciences Ltd's call on order book
Create a free account to keep reading this call
Alivus Life Sciences Ltd — Quarterly revenue & net profit
Alivus Life Sciences Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 689 | 650 | +6% | 673 | +2.4% |
| Operating profit (EBITDA) | 215 | 198 | +8.6% | 231 | -6.9% |
| Operating margin | 31% | 31% | 0 pp | 34% | -3 pp |
| Profit before tax | 216 | 191 | +13.1% | 198 | +9.1% |
| Net profit (PAT) | 163 | 142 | +14.8% | 150 | +8.7% |
| EPS (₹) | 13.25 | 11.58 | +14.4% | 12.25 | +8.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹682 Cr, net profit ₹197 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alivus Life Sciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alivus Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alivus Life Sciences Ltd Q4 FY26 results?
Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins.
What is Alivus Life Sciences Ltd share price analysis?
Alivus Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 26.3 with a market cap of ₹16,341 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alivus Life Sciences Ltd planning capital expenditure?
FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments.
Keep Alivus Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
